Aspar Pharmaceuticals Limited has informed the Medicines and Healthcare products Regulatory Agency (MHRA) that the Patient Information Leaflets (PILs) within various ibuprofen packs are missing some information identified from post-marketing experience that should be documented in Section 3 (How to take the tablets) and Section 4 (Possible side effects) of the PIL.
Further information including details of the affected products, what the PIL should say and advice for healthcare professionals can be found on the MHRA website.
Want the latest pharmacy news and updates straight to your inbox?
Sign up to our regular newsletter for the latest guidance, news, events and CPD opportunities.
Sign Up